A Study of Alisertib in Combination With Endocrine Therapy in Patients With HR-positive, HER2-negative Recurrent or Metastatic Breast Cancer
for Hormone Receptor Positive HER-2 Negative Breast Cancer
35 locations incl. Birmingham
Sponsor: Puma Biotechnology, Inc.
Sex: All·Age: 18+
Code: NCT06369285·Phase 2·Recruiting